

OK to enter EM 6/28/07

USSN 10/052,798

Response and Amendment Under §1.116 and

Contingent Suggestion for Declaration of Interference under 37 C.F.R. § 41.202

**AMENDMENT TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims**

Claims 1-58 (canceled)

59. (Previously Presented) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to an effective amount of an Apo-2 agonist monoclonal antibody which (a) binds to Apo-2 polypeptide consisting of the contiguous amino acid residues 1 to 411 of SEQ ID NO:1 and (b) induces apoptosis in at least one type of mammalian cancer cell *in vivo* or *ex vivo*.
60. (Previously Presented) The method of claim 59 wherein said antibody comprises a single-chain antibody.

Claims 61-64 (canceled)

65. (Currently Amended) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to an effective amount of an Apo-2 agonist monoclonal antibody which (a) binds to a soluble extracellular domain sequence of an Apo-2 polypeptide consisting of amino acids 54 to 182 of SEQ ID NO:1 and (b) induces apoptosis in at least one type of mammalian cancer cell *in vivo* or *ex vivo*.
66. (Previously Presented) A method of inducing apoptosis in mammalian cancer cells comprising exposing mammalian cancer cells to an effective amount of an Apo-2 agonist monoclonal antibody which (a) binds to a soluble extracellular domain sequence of an Apo-2 polypeptide consisting of amino acids 1 to 182 of SEQ ID NO:1 and (b) induces apoptosis in at least one type of mammalian cancer cell *in vivo* or *ex vivo*.